stockrowMadrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) Return on assets
Madrigal Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 September 2026 was −11.1%, up 13.9 percentage points from fiscal 2025 (−25.1%). Over the past ten years it has ranged from −127.0% (fiscal 2016) to −9.68% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −25.1% | 30.32 |
| FY2024 | −55.4% | 19.12 |
| FY2023 | −74.5% | 18.40 |
| FY2022 | −92.9% | (6.57) |
| FY2021 | −86.3% | (30.84) |
| FY2020 | −55.5% | (37.38) |
| FY2019 | −18.1% | (8.42) |
| FY2018 | −9.68% | 17.00 |
| FY2017 | −26.7% | 100.27 |
| FY2016 | −127.0% | (113.40) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 37.7% |
| KRYS Krystal Biotech, Inc. compare | 15.9% |
| PTGX Protagonist Therapeutics, Inc. compare | 10.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| MDGL Madrigal Pharmaceuticals, Inc. | −11.1% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| IBRX ImmunityBio, Inc. compare | −192.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on MDGL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement